Tango Therapeutics, Inc. (TNGX) shareholders
Close on Nov 18, 2026Market cap $3.69BP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| FMR LLC Joint filing with Abigail P. Johnson (15.00%) | 25,286,624 | 15.00% | 13G (passive) amendment | Oct 30, 2026 |
| Linn, Michael G. Joint filing with Dapice Joshua J. (9.80%), Dreyfuss, Philip D. (9.80%) and 13 more | 16,270,187 | 9.80% | 13G (passive) amendment | Jun 30, 2026 |
| TCG Crossover GP II, L.P. Joint filing with Chen Yu (9.99%), TCG Crossover Fund II, L.P. (9.99%) | 13,521,839 | 9.99% | 13G (passive) amendment | Dec 31, 2025 |
| Saito Edric C. Joint filing with Wehrly, Mark C. (9.99%), Dreyfuss, Philip D. (9.99%) and 13 more | 13,461,215 | 9.99% | 13G (passive) amendment | Dec 31, 2025 |
| Roderick Wong Joint filing with RTW Investments, LP (9.30%) | 13,300,620 | 9.30% | 13G (passive) | Mar 31, 2026 |
| TCG Crossover Fund II, L.P. Joint filing with Chen Yu (8.10%), TCG Crossover GP II, LLC (8.10%) | 11,597,737 | 8.10% | 13G (passive) amendment | Mar 31, 2026 |
| Roberts, Jr., Thomas G. Joint filing with Wehrly, Mark C. (7.80%), Dreyfuss, Philip D. (7.80%) and 13 more | 11,257,203 | 7.80% | 13G (passive) amendment | Mar 31, 2026 |
| Giauque, Nicolas Joint filing with Wehrly, Mark C. (9.70%), Dreyfuss, Philip D. (9.70%) and 15 more | 10,757,000 | 9.70% | 13G (passive) amendment | Sep 30, 2025 |
| Davis Aaron I. Joint filing with Boxer Capital Management, LLC (9.70%) | 10,740,385 | 10.00% | 13D (active) amendment | Dec 30, 2024 |
| Robert Atchinson Joint filing with Adage Capital Management, L.P. (7.88%), Phillip Gross (7.88%) | 10,607,924 | 7.88% | 13G (passive) | Dec 31, 2025 |
| TCG Crossover GP II, LLC Joint filing with Chen Yu (7.00%), TCG Crossover Fund II, L.P. (7.00%) | 10,147,867 | 7.00% | 13G (passive) amendment | Jun 30, 2026 |
| Abigail P. Johnson Joint filing with FMR LLC (6.90%) | 9,905,919 | 6.90% | 13G (passive) | Mar 31, 2026 |
| The Goldman Sachs Group, Inc. Joint filing with Goldman Sachs & Co. LLC (6.00%) | 9,742,403 | 6.00% | 13G (passive) | Jun 30, 2026 |
| Trv Gp Iv, LLC Joint filing with Third Rock Ventures GP IV, L.P. (6.97%), Third Rock Ventures IV, L.P. (6.97%) | 9,374,574 | 6.97% | 13D (active) amendment | Nov 12, 2025 |
| Chen Yu Joint filing with TCG Crossover Fund II, L.P. (6.30%), TCG Crossover GP II, LLC (6.30%) | 8,536,196 | 6.30% | 13G (passive) amendment | Sep 30, 2025 |
| BlackRock, Inc. | 8,477,165 | 6.30% | 13G (passive) | Dec 31, 2025 |
| Aaron I. Davis Joint filing with Boxer Capital Management, LLC (6.50%) | 8,339,935 | 7.80% | 13D (active) amendment | Oct 10, 2024 |
| Costas Constantinides Joint filing with Ian Charoub (5.10%), Nextech Crossover I GP S.a. r.l. (5.10%) and 2 more | 7,266,081 | 5.10% | 13G (passive) amendment | Mar 31, 2026 |
| Dunn Hannah E. Joint filing with Wehrly, Mark C. (6.60%), Dreyfuss, Philip D. (6.60%) and 15 more | 7,182,000 | 6.60% | 13G (passive) | Jun 6, 2025 |
| BCTG Holdings, LLC | 6,988,450 | 6.50% | 13D (active) amendment | Nov 6, 2024 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of TNGX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Rtw Investments, LP | 13,900,620 | 8.24% | $434.53M | +600,000 | 3.71% |
| BlackRock, Inc. | 12,438,444 | 7.38% | $388.83M | +3,690,399 | 0.01% |
| FMR LLC | 12,333,339 | 7.31% | $385.54M | +2,427,420 | 0.02% |
| Farallon Capital Management LLC | 12,277,000 | 7.28% | $383.78M | +3,179,589 | 1.77% |
| Boxer Capital Management, LLC | 10,876,219 | 6.45% | $339.99M | – | 25.61% |
| Goldman Sachs Group Inc | 9,980,620 | 5.92% | $311.99M | +4,904,228 | 0.03% |
| TCG Crossover Management, LLC | 9,081,201 | 5.39% | $283.88M | −1,449,870 | 6.82% |
| Trv Gp Iv, LLC | 6,374,574 | 3.78% | $120.18M | – | 47.37% |
| Paradigm Biocapital Advisors LP | 6,357,523 | 3.77% | $198.74M | +2,347,844 | 3.72% |
| Price T Rowe Associates Inc /Md/ | 6,348,827 | 3.77% | $198.47M | +5,459,427 | 0.02% |
| Siren, L.L.C. | 6,179,364 | 3.66% | $193.17M | +522,259 | 3.91% |
| State Street Corp | 5,979,806 | 3.55% | $186.93M | +1,327,912 | 0.01% |
| Vanguard Capital Management LLC | 5,957,348 | 3.53% | $186.23M | +795,917 | 0.00% |
| Adage Capital Partners Gp, L.L.C. | 5,600,000 | 3.32% | $175.06M | −7,209,485 | 0.25% |
| Jupiter Topco LLC | 5,056,352 | 3.00% | $157.99M | New | 0.06% |
| Deep Track Capital, LP | 4,200,000 | 2.49% | $131.29M | +1,450,000 | 1.91% |
| Deerfield Management Company, L.P. (Series C) | 4,190,611 | 2.49% | $131.00M | +43,798 | 1.37% |
| Woodline Partners LP | 4,000,567 | 2.37% | $125.06M | −3,999,446 | 0.39% |
| Geode Capital Management, LLC | 3,742,791 | 2.22% | $117.02M | +1,067,014 | 0.01% |
| Perceptive Advisors LLC | 3,377,000 | 2.00% | $105.57M | +2,568,847 | 1.58% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 247 | 215M | 100.0% | 78 / 102 | 55 / 22 | 68M | 31M |
| Q1 2026 | 194 | 180M | 100.0% | 59 / 64 | 56 / 32 | 48M | 33M |
| Q4 2025 | 170 | 173M | 100.0% | 53 / 75 | 27 / 22 | 73M | 40M |
| Q3 2025 | 141 | 140M | 83.0% | 37 / 48 | 35 / 10 | 27M | 14M |
| Q2 2025 | 115 | 127M | 75.6% | 21 / 41 | 31 / 28 | 28M | 8M |
| Q1 2025 | 122 | 107M | 63.6% | 17 / 43 | 38 / 30 | 13M | 6M |
| Q4 2024 | 137 | 106M | 63.1% | 44 / 40 | 28 / 27 | 41M | 36M |
| Q3 2024 | 121 | 102M | 60.2% | 18 / 39 | 36 / 15 | 15M | 8M |
| Q2 2024 | 120 | 99M | 58.5% | 20 / 38 | 34 / 25 | 4M | 4M |
| Q1 2024 | 126 | 99M | 58.6% | 22 / 36 | 40 / 16 | 12M | 7M |
| Q4 2023 | 121 | 94M | 55.7% | 37 / 42 | 21 / 16 | 14M | 9M |
| Q3 2023 | 100 | 89M | 52.7% | 22 / 33 | 26 / 11 | 22M | 1M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
211 funds held TNGX in Q2 2026, 46% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of TNGX | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 4,395,732 | 2.61% | $137.41M | 0.01% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 3,607,345 | 2.14% | $112.77M | 0.14% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 2,891,041 | 1.71% | $90.37M | 0.84% | Jun 30, 2026 |
| Fidelity Growth Company Fund | 2,472,200 | 1.47% | $54.34M | 0.06% | May 31, 2026 |
| Select Biotechnology Portfolio | 2,339,362 | 1.39% | $51.42M | 0.98% | May 31, 2026 |
| T. Rowe Price New Horizons Fund, Inc. | 1,546,027 | 0.92% | $48.33M | 0.33% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 1,539,756 | 0.91% | $41.85M | 0.12% | Jul 31, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 1,401,293 | 0.83% | $43.80M | 0.37% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 1,365,330 | 0.81% | $42.68M | 0.04% | Jun 30, 2026 |
| iShares Russell 2000 Growth ETF | 1,224,795 | 0.73% | $38.29M | 0.25% | Jun 30, 2026 |
| T. Rowe Price Integrated U.S. Small-Cap Growth Equity Fund | 1,200,590 | 0.71% | $37.53M | 0.38% | Jun 30, 2026 |
| Federated Hermes Kaufmann Fund | 872,500 | 0.52% | $23.71M | 0.48% | Jul 31, 2026 |
| Lord Abbett Developing Growth Fund Inc | 851,196 | 0.50% | $23.14M | 1.04% | Jul 31, 2026 |
| Small Cap Growth Fund | 773,207 | 0.46% | $21.02M | 0.38% | Jul 31, 2026 |
| iShares Biotechnology ETF | 751,469 | 0.45% | $23.49M | 0.26% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Barbara Weber | Director, Executive Chair | 1,629,587 | 0.97% | Feb 4, 2026 |
| Malte Peters | President & CEO, Director | 367,500 | 0.22% | Jan 12, 2026 |
| Adam Crystal | President, R&D | 115,743 | 0.07% | Nov 13, 2026 |
| Jessica Newcomb | Principal Accounting Officer | 52,090 | 0.03% | Nov 4, 2026 |
| Matthew Gall | Chief Financial Officer | 40,000 | 0.02% | May 5, 2026 |
| Daniella Beckman | Chief Financial Officer | 184,297 | 0.11% | Feb 4, 2026 |
| Douglas Barry | General Counsel | 66,014 | 0.04% | Feb 6, 2025 |
| Robert Azelby | Director | 5,740 | 0.00% | Jun 23, 2026 |
| Lesley Ann Calhoun | Director | 16,500 | 0.01% | Jun 8, 2026 |
| John B. Ketchum | Director | 24,937 | 0.01% | Jun 8, 2026 |
| Sung Lee | Director | 22,870 | 0.01% | Jun 8, 2026 |
| Mace Rothenberg | Director | 41,500 | 0.02% | Jun 8, 2026 |
| Alexis Borisy | Director | 17,500 | 0.01% | Jun 9, 2025 |
| Third Rock Ventures GP IV, L.P. | 10% owner | 15,456,881 | 9.17% | Oct 27, 2025 |
| Third Rock Ventures IV, L.P. | 10% owner | 17,001,475 | 10.08% | Oct 27, 2025 |
| Trv Gp Iv, Llc | 10% owner | 13,386,574 | 7.94% | Oct 27, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Adam Crystal President, R&D | Nov 11, 2026 | Sale(10b5-1 plan) | −5,000 | $25.00 | $125.00K | 115,743 |
| Adam Crystal President, R&D | Nov 11, 2026 | Option exercise | +5,000 | $2.91 | $14.55K | 120,743 |
| Adam Crystal President, R&D | Nov 2, 2026 | Sale(10b5-1 plan) | −1,100 | $22.99 | $25.29K | 115,743 |
| Adam Crystal President, R&D | Nov 2, 2026 | Sale(10b5-1 plan) | −3,900 | $22.26 | $86.82K | 116,843 |
| Adam Crystal President, R&D | Nov 2, 2026 | Option exercise | +5,000 | $2.91 | $14.55K | 120,743 |
| Jessica Newcomb Principal Accounting Officer | Nov 2, 2026 | Sale(10b5-1 plan) | −1,460 | $22.98 | $33.55K | 52,090 |
| Jessica Newcomb Principal Accounting Officer | Nov 2, 2026 | Sale(10b5-1 plan) | −5,571 | $22.28 | $124.11K | 53,550 |
| Adam Crystal President, R&D | Oct 1, 2026 | Sale(10b5-1 plan) | −600 | $25.32 | $15.19K | 115,743 |
| Adam Crystal President, R&D | Oct 1, 2026 | Sale(10b5-1 plan) | −26,400 | $24.45 | $645.60K | 116,343 |
| Adam Crystal President, R&D | Oct 1, 2026 | Option exercise | +27,000 | $5.20 | $140.40K | 142,743 |
| Jessica Newcomb Principal Accounting Officer | Sep 22, 2026 | Sale(10b5-1 plan) | −700 | $22.80 | $15.96K | 66,621 |
| Jessica Newcomb Principal Accounting Officer | Sep 22, 2026 | Sale(10b5-1 plan) | −5,100 | $23.97 | $122.25K | 61,521 |
| Jessica Newcomb Principal Accounting Officer | Sep 22, 2026 | Sale(10b5-1 plan) | −2,400 | $25.17 | $60.41K | 59,121 |
| Adam Crystal President, R&D | Sep 1, 2026 | Option exercise | +27,000 | $5.20 | $140.40K | 142,743 |
| Adam Crystal President, R&D | Sep 1, 2026 | Sale(10b5-1 plan) | −27,000 | $22.37 | $603.99K | 115,743 |
| Adam Crystal President, R&D | Aug 3, 2026 | Option exercise | +27,000 | $5.20 | $140.40K | 142,743 |
| Adam Crystal President, R&D | Aug 3, 2026 | Sale(10b5-1 plan) | −5,267 | $26.79 | $141.10K | 137,476 |
| Adam Crystal President, R&D | Aug 3, 2026 | Sale(10b5-1 plan) | −21,733 | $27.35 | $594.40K | 115,743 |
| Adam Crystal President, R&D | Jul 1, 2026 | Sale(10b5-1 plan) | −19,629 | $29.34 | $575.91K | 123,114 |
| Adam Crystal President, R&D | Jul 1, 2026 | Sale(10b5-1 plan) | −7,371 | $30.25 | $222.97K | 115,743 |
| Adam Crystal President, R&D | Jul 1, 2026 | Option exercise | +27,000 | $5.20 | $140.40K | 142,743 |
| Robert Azelby Director | Jun 19, 2026 | Award | +5,740 | – | – | 5,740 |
| Mace Rothenberg Director | Jun 5, 2026 | Award | +4,000 | – | – | 41,500 |
| Sung Lee Director | Jun 5, 2026 | Award | +570 | – | – | 22,870 |
| John B. Ketchum Director | Jun 5, 2026 | Award | +4,000 | – | – | 24,937 |
| Lesley Ann Calhoun Director | Jun 5, 2026 | Award | +4,000 | – | – | 16,500 |
| Adam Crystal President, R&D | Jun 1, 2026 | Sale(10b5-1 plan) | −6,140 | $22.25 | $136.62K | 136,603 |
| Adam Crystal President, R&D | Jun 1, 2026 | Sale(10b5-1 plan) | −20,860 | $23.06 | $481.03K | 115,743 |
| Adam Crystal President, R&D | Jun 1, 2026 | Option exercise | +27,000 | $5.20 | $140.40K | 142,743 |
| Matthew Gall Chief Financial Officer | May 1, 2026 | Award | +40,000 | – | – | 40,000 |
| Adam Crystal President, R&D | May 1, 2026 | Sale(10b5-1 plan) | −1,100 | $22.00 | $24.20K | 115,743 |
| Adam Crystal President, R&D | May 1, 2026 | Option exercise | +27,000 | $5.20 | $140.40K | 142,743 |
| Adam Crystal President, R&D | May 1, 2026 | Sale(10b5-1 plan) | −25,900 | $21.19 | $548.82K | 116,843 |
| Sung Lee Director | Apr 29, 2026 | Award | +12,300 | – | – | 22,300 |
| Adam Crystal President, R&D | Apr 15, 2026 | Sale(10b5-1 plan) | −38,460 | $25.00 | $961.50K | 112,622 |
| Adam Crystal President, R&D | Apr 15, 2026 | Option exercise | +38,460 | $5.20 | $199.99K | 151,082 |
| Adam Crystal President, R&D | Apr 1, 2026 | Option exercise | +27,000 | $5.20 | $140.40K | 139,622 |
| Adam Crystal President, R&D | Apr 1, 2026 | Sale(10b5-1 plan) | −27,000 | $21.20 | $572.40K | 112,622 |
| Adam Crystal President, R&D | Mar 25, 2026 | Sale(10b5-1 plan) | −12,000 | $20.11 | $241.32K | 112,622 |
| Adam Crystal President, R&D | Mar 25, 2026 | Option exercise | +12,000 | $5.20 | $62.40K | 124,622 |
| Adam Crystal President, R&D | Mar 5, 2026 | Sale(10b5-1 plan) | −20,251 | $15.00 | $303.77K | 112,622 |
| Adam Crystal President, R&D | Feb 25, 2026 | Sale(10b5-1 plan) | −54,345 | $12.77 | $693.99K | 132,873 |
| Barbara Weber Director, Executive Chair | Feb 3, 2026 | Sale | −30,186 | $12.26 | $370.08K | 1,629,587 |
| Barbara Weber Director, Executive Chair | Feb 3, 2026 | Sale | −333 | $12.90 | $4.30K | 1,629,254 |
| Daniella Beckman Chief Financial Officer | Feb 3, 2026 | Sale | −113 | $12.90 | $1.46K | 184,297 |
| Daniella Beckman Chief Financial Officer | Feb 3, 2026 | Sale | −10,204 | $12.26 | $125.10K | 184,410 |
| Adam Crystal President, R&D | Feb 3, 2026 | Sale | −18,251 | $12.26 | $223.76K | 187,419 |
| Adam Crystal President, R&D | Feb 3, 2026 | Sale | −201 | $12.90 | $2.59K | 187,218 |
| Barbara Weber Director, Executive Chair | Feb 2, 2026 | Award | +37,522 | – | – | 1,659,773 |
| Daniella Beckman Chief Financial Officer | Feb 2, 2026 | Award | +44,330 | – | – | 194,614 |
| Adam Crystal President, R&D | Feb 2, 2026 | Award | +47,460 | – | – | 205,670 |
| Malte Peters President & CEO, Director | Jan 8, 2026 | Award | +350,000 | – | – | 367,500 |
| Sung Lee Director | Jan 2, 2026 | Award | +10,000 | – | – | 10,000 |
| Trv Gp Iv, Llc 10% owner | Oct 23, 2025 | Sale | −477,401 | $10.15 | $4.85M | 13,386,574 |
| Trv Gp Iv, Llc 10% owner | Sep 25, 2025 | Sale | −500,000 | $8.02 | $4.01M | 13,863,975 |
| Trv Gp Iv, Llc 10% owner | Sep 16, 2025 | Sale | −363,541 | $7.04 | $2.56M | 14,363,975 |
| Trv Gp Iv, Llc 10% owner | Sep 8, 2025 | Sale | −86,459 | $7.04 | $608.67K | 14,727,516 |
| Trv Gp Iv, Llc 10% owner | Sep 5, 2025 | Sale | −642,906 | $7.00 | $4.50M | 14,813,975 |
| Third Rock Ventures GP IV, L.P. 10% owner | Aug 22, 2025 | Sale | −302,194 | $7.00 | $2.12M | 15,456,881 |
| Third Rock Ventures GP IV, L.P. 10% owner | Aug 19, 2025 | Sale | −1,100,000 | $7.01 | $7.71M | 15,759,075 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Tango Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 491,105 shares on Sep 24, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Adam Crystal Officer | Nov 2, 2026 | 20,000 | $454.40K | Nov 2, 2026 | Exercise of Stock Options |
| Jessica Newcomb Officer | Sep 22, 2026 | 15,231 | $340.11K | Sep 22, 2026 | Restricted Stock Units |
| Adam Crystal Officer | Aug 3, 2026 | 81,000 | $2.20M | Aug 3, 2026 | Exercise of Stock Options |
| Nextech Crossover I SCSp Former Affiliate | Jun 17, 2026 | 3,766,081 | $113.36M | Jun 17, 2026 | Private Placement |
| Daniella Beckman Officer | Jun 11, 2026 | 1,791,726 | $51.52M | Jun 11, 2026 | Stock Option Exercise |
| Daniella Beckman Officer | Jun 10, 2026 | 4,446 | $133.38K | Jun 10, 2026 | Stock Option Exercise |
| Adam Crystal Officer | May 1, 2026 | 65,460 | $1.42M | May 1, 2026 | Exercise of Stock Options |
| Adam Crystal Officer | Mar 25, 2026 | 93,000 | $1.81M | Mar 25, 2026 | Exercise of Stock Options |
| Adam Crystal Officer | Mar 5, 2026 | 20,251 | $250.10K | Mar 5, 2026 | Exercise of Stock Options |
| Adam Crystal Officer | Feb 25, 2026 | 54,345 | $699.96K | Feb 25, 2026 | Restricted Stock Units |
| Third Rock Ventures IV, L.P. 10% Stockholder | Oct 23, 2025 | 477,401 | $3.59M | Oct 23, 2025 | Pre-IPO investment |
| Third Rock Ventures IV, L.P. 10% Stockholder | Sep 25, 2025 | 500,000 | $3.90M | Sep 25, 2025 | Pre-IPO investment |
| Third Rock Ventures IV, L.P. 10% Stockholder | Sep 17, 2025 | 363,541 | $2.67M | Sep 16, 2025 | Pre-IPO investment |
| Third Rock Ventures IV, L.P. 10% Stockholder | Sep 8, 2025 | 86,459 | $608.63K | Sep 8, 2025 | Pre-IPO investment |
| Third Rock Ventures IV, L.P. 10% Stockholder | Sep 5, 2025 | 642,906 | $4.46M | Sep 5, 2025 | Pre-IPO investment |
See a number that looks wrong?